Targeted protein degradation: species, diseases and efficient utilization Authors: Tian Yue, Jian He, Jun Hou Published: 2025 ABSTRACT BackgroundTargeted protein degradation (TPD) is a novel protein modulation strategy distinct from traditional inhibitors. Its core mechanism involves labeling proteins of interest to initiate endogenous protein clearance pathways, mainly including the ubiquitin-proteasome system (UPS) pathway and the lysosomal pathway. TPD has emerged as a promising therapeutic approach for various diseases, but its clinical translation and therapeutic efficacy are hindered by limitations of TPD formulations such as poor bioavailability and off-target effects.​.Main bodyThis review first elaborates on the different types of TPD strategies and their respective implementation mechanisms. Subsequently, it summarizes the current research status of TPD in major disease fields, including tumor therapy (with a focus on the regulation of key proteins such as Bruton Tyrosine Kinase, Androgen Receptor, Estrogen Receptor, and cell cycle-related proteins), neurodegenerative diseases, and inflammatory/immune diseases. Additionally, the potential of drug delivery systems to address the aforementioned limitations of TPD formulations is discussed, as they may substantially enhance TPD therapeutic efficacy.​ConclusionsThis review provides a comprehensive overview of current TPD types, their research progress in different diseases, and strategies for effective application of TPD. It is expected to offer valuable guidance for the development of TPD formulations and promote their clinical translation. Introduction Targeted protein degradation (TPD), an emerging technology for drug discovery [1, 2]. It is mainly realized through the ubiquitin-proteasome system (UPS) or autophagy-lysosome pathway [3, 4]. The core design idea of TPD is to “tag” the target proteins to be degraded, so that they can be recognized and cleared by intracellular degradation mechanisms [5, 6]. For example, protein hydrolysis-targeted chimeras (PROTACs) link target proteins to E3 ubiquitin ligases through bifunctional molecules, allowing the target protein to be ubiquitinated and then degraded by the proteasome; molecular gels induce new interactions between the target proteins and the E3 ligases to trigger degradation [7, 8]. Lysosome-targeted chimeras (LYTACs) transport target proteins to the lysosome for degradation with the help of a bifunctional molecule, and are suitable for extracellular secretory or membrane proteins [9]. Autophagy-targeting Chimeras (AUTACs) recruits target proteins to autophagosomes or directly binds autophagy-associated proteins for degradations via the autophagy-lysosome pathway through different mechanisms, which provides diverse strategies for precise regulation of protein function(Table 1) [10]. The catalytic mechanism of action and event-driven pharmacology make PROTACs have more advantages than traditional small molecule drugs. (1) wider target range, still effective on many “non-druggable” targets [11]. (2) high efficiency degradation, POI removal effect can be achieved under the amount of catalyst [12]. (3) overcoming resistance, still effective in combating resistant proteins [13]. (4) precise regulation, targeting proteins can more accurately regulate intracellular signaling pathways and physiological processes [14]. (5) potential combination therapy development, such as combining chemotherapy, radiotherapy and immunotherapy in tumor treatment [15]. TPDs are used in tumor therapy to degrade oncogenic proteins such as mutant p53 (An important tumor suppressor protein) [16], Breakpoint Cluster Region-Abelson (BCR-ABL) [17], etc. Preclinical studies have shown their potential for overcoming drug resistance [18], e.g., the PROTAC drugs ARV-471 [19] (targeting Estrogen Receptorα, ERα) and ARV-110 [20] (targeting Androgen Receptor, AR) are in the clinical stage. In neurodegenerative diseases, TPD can remove α-synaptic nucleoprotein [21], tau protein and other abnormal aggregated proteins [22], exploring the treatment of Alzheimer’s disease (AD). In immune diseases, TPD is in the research stage of targeting pro-inflammatory cytokines, such as Interleukin-6 (IL-6) [23], Signal Transducer and Activator of Transcription 3 (STAT3) [24], and the degradation of agents. Although TPDs show great therapeutic potential in the above targets and diseases, TPDs are still limited in research and application due to solubility, permeability, susceptibility to biodegradation leading to low bioavailability, and off-targeting and toxicity due to unrestricted and undifferentiated cellular protein degradation [25–27]. Therefore, precise delivery of TPDs to target organs or tissues is a problem that must be addressed during the development of TPDs [25]. Through targeted ligands or nanomedicine delivery systems, receptor-mediated or nanoparticle passive and active delivery can be realized, thus precisely delivering TPDs to target tissues or organs. This greatly enhances solubility, tissue penetration and reduces the risk of off-target toxicity, while at the same time giving TPDs the ability to be released in a controlled manner [28, 29]. This paper reviews the main classes of TPDs, the main research targets and indications, and discusses optimized design ideas, existing or potential indications of TPDs (Fig. 1). To enhance the clinical translational possibilities of TPDs, the introduction of nanotechnology has also provided new ideas for the optimization of TPDs, and therefore, this paper also summarizes the advanced drug delivery systems used for TPDs drugs. This paper can provide ideas and facilitate the transition of TPDs from research to the clinic for TPDs design, application, translation and delivery. Fig. 1Schematic illustration of major TPD strategies and the UPS-mediated protein degradation process. It depicts three representative TPD approaches: (A) PROTAC, a bifunctional molecule that recruits an E3 ubiquitin ligase to the POI; (B) Molecular glues, which induce proximity between POI and E3 ligase to promote ubiquitination; (C) Hydrophobic segment- and PQC-based strategy, where hydrophobic moieties and PQC components mediate POI degradation. The lower panel outlines the UPS cascade: E1 ubiquitin-activating enzyme activates ubiquitin (Ub) in an ATP-dependent manner, transfers Ub to E2 ubiquitin-conjugating enzyme, and E3 ligase then mediates POI ubiquitination. Polyubiquitinated POI is subsequently recognized and degraded by the 26S proteasome Schematic illustration of major TPD strategies and the UPS-mediated protein degradation process. It depicts three representative TPD approaches: (A) PROTAC, a bifunctional molecule that recruits an E3 ubiquitin ligase to the POI; (B) Molecular glues, which induce proximity between POI and E3 ligase to promote ubiquitination; (C) Hydrophobic segment- and PQC-based strategy, where hydrophobic moieties and PQC components mediate POI degradation. The lower panel outlines the UPS cascade: E1 ubiquitin-activating enzyme activates ubiquitin (Ub) in an ATP-dependent manner, transfers Ub to E2 ubiquitin-conjugating enzyme, and E3 ligase then mediates POI ubiquitination. Polyubiquitinated POI is subsequently recognized and degraded by the 26S proteasome Current molecular classes of TPDs Degradation of proteins can be achieved through UPS and Lysosomal Pathways, which are important processes for maintaining Protein homeostasis [30]. TPD utilizing UPS focuses on protein degradation, which is currently being studied more extensively [13]. In contrast, TPD that relies on the lysosomal pathway is currently being studied for a shorter period but can be effective in targeting organelles [31]. UPS-based TPD The keyways of UPS consist of ubiquitin, the ubiquitination enzyme system, and the 26S proteasome, and involves three processes. E1 is fed by ATP hydrolysis and covalently binds the ubiquitin molecule, which is then passed to E2. E3 recognizes the target protein and catalyzes the binding of ubiquitin to lysine residues of the target protein and results in the ubiquitination of protein of interest (POI) [32, 33]. Among them, E3 is involved in the recognition and ubiquitination of POI during UPS and plays a decisive role in protein selection [34]. The screening and application of E3 ubiquitin ligases are critical for the development and translation of PROTACs [35]. In current research, commonly used E3 ubiquitin ligases (such as CRL4CRBN, VHL, etc.) have limitations: some of these enzymes exhibit low tissue specificity, which may induce off-target toxicity, and others show insufficient ubiquitination efficiency toward specific targets, thus limiting the therapeutic response rate [35, 36]. In contrast, alternative E3 ubiquitin ligases (such as RNF41, HUWE1, ITCH, etc.) can compensate for the aforementioned limitations by virtue of their unique substrate recognition domains, tissue expression profiles, or regulatory mechanisms [37]. Selecting appropriate alternative E3 ubiquitin ligases based on different disease subtypes or target characteristics can enhance the specificity and efficacy of targeted therapy. Furthermore, the diversity of alternative E3 ubiquitin ligases enables the “one-target-multiple-enzymes” or “multi-target-multi-enzymes” combination strategies, covering more refractory disease scenarios (such as drug-resistant tumors and multi-target-driven diseases) [38, 39]. The ubiquitination-dependent process to initiate the TPD process consists of classical PROTACs [40], molecular glues [41, 42], Hydrophobic tagging (HyT) [43], dual-PROTAC [44], and selective androgen/estrogen receptor degrader (SARD/SERD) [45, 46]. PROTACs are bifunctional molecules containing a target protein binding ligand for recognizing and binding to POIs, a Linker for connecting the target protein ligand to the E3 ubiquitin ligase ligand, and an E3 ubiquitin ligase ligand that binds to E3 ubiquitin ligases such as Cereblon (CRBN), von Hippel-Lindau tumor suppressor protein (VHL), etc. in the cell (Fig. 1) [47, 48]. PROTACs bind both the target protein and E3 ubiquitin ligase, forming a “target protein-PROTAC-E3 enzyme” ternary complex. Subsequently, the ubiquitinated target protein is recognized by the proteasome and degraded to a short peptide [49]. Due to their non-occupancy-driven mechanism, PROTACs are released and recycled to clear POIs after they take effect, so a small number of PROTACs molecules can degrade many target proteins, resulting in a theoretically lower dosage of medication, lower risk of resistance, and longer duration of efficacy due to the fact that PROTACs can be dissociated and reutilized [50, 51]. For example, a study developed selective ER-degrading PROTACs called ARV-471 for the treatment of estrogen receptor-positive (ER+) breast cancer. Compared to conventional ER inhibitors, ARV-471 demonstrated more efficient ER clearance efficiency and long-term protein level regulation [19]. More promisingly, many recently developed ER-degraded PROTACs have demonstrated far superior therapeutic effects to ARV-471. For example, ERD-12,310 A showed superior pharmacokinetic profiles to ARV-471 in both mice and rats and achieved potent tumor growth inhibition in clinically relevant ERα-carrying MCF-7 (Classical human-derived breast cancer cell lines) xenografts with 10-fold potency compared to ARV-471 [52]. In addition, the mechanism of action of PROTACs also confers on them the ability to expand the druggable POI (Table 1), which is a central point that distinguishes them from other protein-targeted drugs. Taking Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein as an example, KRAS protein was once considered as a “non-druggable” target due to the lack of targetable pocket structure, however, due to the discovery of KRAS binding site in the previous studies and the successful degradation of PROTACs (named ACBI3) developed by utilizing VHL as a ubiquitin ligase to degrade KRAS, the researchers found that ACB13 was still effective in targeting mutant proteins of KRAS [53]. Moreover, while traditional kinase inhibitors often cause resistance through mutation or overexpression of the drug target, PROTACs minimize resistance through degradation of target proteins that are subject to long-term selection pressure. For example, mutation of cysteine to serine at position 481 of the Bruton’s Tyrosine Kinase (BTK) protein leads to resistance to ibrutinib. PROTACs developed on this basis achieve efficient clearance of multiple mutant BTK proteins (C481S/T/A/G/W) [54]. ARV825 is a PROTAC that acts on Bromodomain Containing Protein 4 (BRD4) and is effective in multiple myeloma cells resistant to bortezomib, lenalidomide, dexamethasone and other drugs [55]. PROTACs have shown great potential for valuable applications in protein scavenging, however, a number of factors have limited the application and clinical translation of PROTACs, including stability, tissue distribution, effective E3 ligase ligands, and potential toxicity and off-target effects [56, 57]. The discovery of novel E3 ligases, innovations in delivery systems such as lipid nanoparticles (LNPs) and peptide carriers, breaking the bottleneck of bioavailability, and combining PROTACs with immunotherapy and chemotherapy can enhance the application of PROTACs in different diseases and facilitate the translation of PROTACs into clinical drugs. Molecular glues are a class of small molecule compounds that induce specific interactions of target proteins with E3 ubiquitin ligases (Fig. 1B) [58]. Compared to PROTACs, molecular glues usually have smaller molecular weights and exhibit better oral and cellular penetration effects due to the absence of a linker component in the design and development of molecular glues [59, 60]. Unlike protein inhibitors or PROTACs (which need to bind both the target protein and the E3 ligase), molecular gels usually need to bind only one of the target proteins (often the E3 ligase, e.g., CRBN, VHL, etc.), and by changing their conformation or exposing new binding interfaces, they can induce ternary complexes between the unbound target proteins and E3 ligases, and then induce POI to ubiquitylate and be degraded by the proteasome [61]. Taking thalidomide as an example, thalidomide and its derivatives (e.g., lenalidomide, pomalidomide) bind to CRBN, inducing a conformational change in the CRBN, causing it to abnormally recognize and recruit the degradation of proteins such as Immunoglobulin Zinc Finger Protein 1/3 (IKZF1/3) [62], and Casein Kinase 1 alpha (CK1α) [63], which inhibit the proliferation of tumor cells, induce apoptosis, and regulate the immune microenvironment. In myelodysplastic syndromes (MDS), CK1α degradation restores normal hematopoiesis [64]. In addition, thalidomide has been found to degrade guanine nucleotide binding protein 1 (GSPT1), triggering apoptosis in tumor cells [65]. However, the greatest risk of molecular glues, i.e., unintended protein degradation, may lead to unintended degradation of homologous or similarly structured proteins in normal tissues, resulting in toxicity [66]. Moreover, molecular glues are UPS-dependent and may interfere with normal cellular metabolism if multiple proteins are degraded at the same time or E3 ligase is consumed in large quantities, which may lead to cellular stress such as endoplasmic reticulum stress, cell necrosis or apoptosis [67]. Like PROTACs, Hyt possesses a three-part structure consisting of a small-molecule ligand that binds to the POI, a hydrophobic tag, and a Linker. Among other things, Hyt is recognized by molecular chaperone proteins as a misfolded protein state by mimicking the hydrophobic amino acids exposed on the surface of proteins and promotes POIs degradation by proteasomes or lysosomes by recruiting protein quality control (PQC) proteins (Fig. 1C) [68, 69]. The molecular weight of Hyt was also lower compared with that of PROTACs. The selection of Hyt determines the efficiency of Hyt-induced protein degradation, and small molecule structural compounds with strong hydrophobicity are usually chosen, such as icariene [70], D-cycloconjugated artemisinin [71]. Taking icariene as an example, Shaowen Xie et al. developed a Hyt named Hyt-9, which utilizes anaplastic lymphoma kinase (ALK) inhibitors to recognize and connect ALK protein and effectively degrades ALK via the strong hydrophobic icariene via Heat Shock Protein 70 (Hsp70) and UPS. Surprisingly, it was found in a follow-up study that Hyt-induced ALK degradation did not lead to compensatory up-regulation of ALK and demonstrated significant tumor suppression in an in vivo study [70]. Dual-PROTAC is an optimized solution for PROTACs, capable of simultaneously degrading two dual-targeted degradation molecules with completely different pathway targets. This is achieved by combining two target proteins with an E3 ligase (typically one E3 ligase), which induces ubiquitination of the two target proteins, leading to their degradation by the proteasome [72]. A study synthesized dual-targeted degradation chimeric molecules of epidermal growth factor receptor (EGFR) and poly(adp-ribose)polymerase (PARP) proteins (Dual-PROTACs) with different linkage lengths and recruited by different E3 ligases (CRBN and VHL), using the EGFR inhibitor gefitinib and the PARP inhibitor olaparib as raw materials. The molecules were demonstrated to successfully degrade both EGFR and PARP proteins in cancer cells at the cellular level, which is the first successful example of Dual-PROTACs [73]. SARDs interact with the AR to induce degradation of the AR, thereby downregulating its expression. In this way, SARDs can inhibit the androgen signaling pathway, which plays a key role in the development of androgen-dependent diseases such as prostate cancer, and current popular SARDs include ARV-110 [74], ARV-766 [75], CC-94,676 [76], etc. SERDs selectively bind to the estrogen receptor (ER), inducing a conformational change, which in turn recruits the relevant intracellular mechanisms to degrade ER proteins, effectively inhibiting estrogen signaling in cancer cells and thus suppressing tumor growth [77, 78]. Fulvestrant is a commonly used SERD in clinical practice for the treatment of locally advanced or metastatic postmenopausal estrogen receptor-positive breast cancer that has recurred after or during anti-estrogen therapy or has progressed during anti-stimulant therapy [79]. Lysosomal-based TPD Lysosomal pathways degrade into a wider range of proteins [80], lipids, nucleic acids, and damaged organelles. Depending on the mode of substrate entry into the lysosome, there are three major pathways: Endocytosis [81], Autophagy [82] and Chaperone-Mediated Autophagy (CMA) [83]. TPDs based on Lysosomal pathways usually contain target protein binding receptors and lysosomal targeting signals and direct the target protein-TPD complex to be captured by the lysosome, enter the lysosome via endocytosis or autophagy pathway, and ultimately be degraded by hydrolases. Current studies include LYTACs [84], antibody-based PROTACs (ABTACs) [85], autophagy-targeted chimeras (AUTACs) [86], autophagy-tethered compounds (ATTECs) [87], and targeted degradation compounds based on CMAs [88]. LYTACs function by bridging extracellular/membrane target proteins with lysosomal targeting receptors via a bifunctional structure, triggering endocytosis and subsequent degradation of the target in lysosomes [89]. LYTACs has already demonstrated its potential in a variety of areas, including tumor therapy, chronic eye disease, and neurodegenerative diseases (Fig. 2). A recent study by Yunjia Li et al. showed that JW-9, a target-degrading compound synthesized by LYTAC technology against heparanase (HPA1) in the microenvironment of hepatocellular carcinoma, cleverly utilized the asialoglycoprotein receptor (ASGPR) system, which is the body’s system for removing aging proteins, to degrade HPA1, which is the target of hepatoma, and made use of the lysosomal system of the hepatocellular carcinoma cells to degrade immunosuppressive molecules, thus enhancing the anti-hepatocellular carcinoma effect of NK cells. The lysosomal system of liver cancer cells is used to degrade immunosuppressive molecules of liver cancer, thus enhancing the anti-liver cancer effect of natural killer (NK) cells [90]. Due to the low bioavailability and non-specific distribution of LYTACs, LYTACs have not yet been widely promoted. Therefore, it is imperative to develop a LYTACs system that can selectively target tumor tissues and realize modular design, which will be beneficial to broaden the therapeutic window [91]. Fig. 2Schematic illustration of diverse lysosome mediated and autophagy lysosome pathway dependent targeted protein degradation strategies. The diagram depicts that LYTACs recruit LTRs at the cell membrane to form ternary complexes with POI, which then undergo mesh protein mediated endocytosis, traffic to endosomes, and are ultimately delivered to lysosomes for degradation. The AbTACs mediate the formation of EGFR-AbTAC-POI ternary complexes, these complexes are internalized into endosomes and subsequently directed to lysosomes. Additionally, a pathway involving K63-linked polyubiquitination of POI allows recognition by autophagy receptors, triggering autophagosome formation and subsequent delivery to lysosomes for degradation Schematic illustration of diverse lysosome mediated and autophagy lysosome pathway dependent targeted protein degradation strategies. The diagram depicts that LYTACs recruit LTRs at the cell membrane to form ternary complexes with POI, which then undergo mesh protein mediated endocytosis, traffic to endosomes, and are ultimately delivered to lysosomes for degradation. The AbTACs mediate the formation of EGFR-AbTAC-POI ternary complexes, these complexes are internalized into endosomes and subsequently directed to lysosomes. Additionally, a pathway involving K63-linked polyubiquitination of POI allows recognition by autophagy receptors, triggering autophagosome formation and subsequent delivery to lysosomes for degradation ABTACs, an antibody-based PROTACs ABTACs utilize the lysosomal degradation pathway that is naturally present in the cell to achieve degradation of the target protein (Fig. 2). ABTACs are bispecific antibodies that simultaneously bind membrane-bound E3 ligases and target membrane proteins, forming ternary complexes to induce internalization and degradation via lysosomal or ubiquitin-proteasome pathways [92, 93]. They show promising potential in cancer immunotherapy and viral infections by specifically degrading refractory membrane proteins, leveraging the high specificity of antibodies [85]. However, ABTACs are limited by their dependence on the expression of specific membrane E3 ligases in target cells, challenges in optimizing in vivo stability and tissue penetration, and inability to target intracellular or extracellular soluble proteins [31]. Adam D Cotton et al. found that PROTACs based on ABTACs were effective in reducing degradation of programmed death ligand 1 (PD-L1) and improving immune checkpoint inhibition in tumors [94]. ABTACs have higher specificity and affinity, which can target the target protein more precisely and reduce the effect on other non-target proteins. Meanwhile, ABTACs can target proteins that are difficult for traditional small molecule drugs to work on, such as membrane proteins, expanding the range of drugable targets [85, 94]. The AUTAC molecule consists of two parts, one of which is an intracellular target protein-specific binding agent that recognizes and binds to the target protein, and the other part is a degradation tag, usually a guanine derivative, that is used to mimic post-translational modifications (Fig. 2) [94, 95] Such as S-guanineosylation. The AUTAC molecule binds to the target protein via its target protein conjugate, and then its degradation tag mimics S-guanineosylation, inducing K63-polyubiquitination of the target protein [96]. This K63-polyubiquitinated protein is recognized by the selective autophagy pathway, which transports the target protein to the autophagy-lysosomal pathway for degradation [95]. They hold significant potential for treating neurodegenerative diseases (characterized by protein aggregates) and cancer, as they can target intracellular proteins, damaged organelles, and substrates inaccessible to E3 ligase-dependent PROTACs [97]. In a recent study by Ligang Mei et al. Their findings indicated that linking large target models to phagophore-associated ATG16L1 or LC3 triggered the targeted autophagic degradation of these large target models. Moreover, this autophagy-targeting degradation strategy was successfully implemented for the targeted degradation of HTT65Q aggregates and mitochondria [98]. Currently, there are insufficient data on the long-term safety and potential side effects of AUTACs as a unique therapeutic approach, and further research is still needed. However, AUTACs are limited by their reliance on intact cellular autophagic activity, potential off-target activation of autophagy, and challenges in optimizing in vivo stability and tissue-specific delivery [2]. Autophagy-Targeting Chimeras (AUTACs) function by using cGMP-based degradation tags to induce K63-linked polyubiquitination of target proteins, which are then recognized by autophagy receptors (e.g., p62/SQSTM1) and degraded through autophagosome-lysosome fusion. ATTECs consist of three parts. One is the binding molecule of autophagosomal protein LC3, such as GW5074; the second is the lipid droplet-specific binding molecule, such as Sudan IV or Sudan III and other LD detection probes; and the third is the Linker. ATTECs bind to lipid droplets or neutral lipids through hydrophobic interaction at one end, and the other end binds to the autophagosomal protein LC3 to form a lipid droplet/neutral lipid-LD-ATTEC-LC3 ternary complex. Lipid droplet/neutral lipid-LD-ATTEC-LC3 ternary complex is formed. The complex is engulfed by autophagosomes and subsequently degraded by autophagy, and eventually converted to energy by mitochondria [99]. Based on CMA degradates. The core process of CMA relies on the specific recognition of a molecular chaperone (e.g., the heat shock protein HSP70) with a target protein and the formation of a chaperone-target protein complex. The complex is then transported to the surface of the lysosomal membrane, where it binds to a monomer of lysosome-associated membrane protein 2 A (LAMP2A), which induces LAMP2A oligomerization to form a transmembrane channel. Finally, the target protein unfolds through the channel and enters the lysosome, where it is degraded by lysosomal proteases (e.g., histone protease) into amino acids for cellular recycling [100]. Table 1The current mainstream TDP types and representative moleculesMajor TPD categorySpecific molecular classMolecular structure compositionMechanism of actionRepresentative molecules/examplesKey advantagesUPS-based TPDPROTACs (Proteolysis-Targeting Chimeras)(1) Protein of Interest (POI)-binding ligand; (2) Linker (connects ligands); (3) E3 Ubiquitin Ligase ligand (e.g., CRBN, VHL)Forms a “POI-PROTAC-E3” ternary complex → ubiquitination of POI → degradation of POI into short peptides by proteasome;ARV-471ERD-12,310 AARV-471ACBI3ARV825(1) Non-occupancy-driven, recyclable; (2) Low dosage, low resistance risk, long-lasting efficacy; (3) Expands druggable targets (e.g., KRAS)Molecular GluesSmall molecules, no Linker componentBinds to E3 ubiquitin ligase (e.g., CRBN, VHL) → alters conformation/exposes new binding interfaces → induces POI-E3 interaction → ubiquitination and degradation of POIThalidomide and derivatives(1) Small molecular weight; (2) Excellent oral absorption and cellular penetration; (3) No need to bind both POI and E3HyT (Hydrophobic Tagging Degraders)(1) POI-binding ligand; (2) Linker; (3) Hydrophobic tag (e.g., icariene, D-cycloconjugated artemisinin)Mimics hydrophobic amino acids on protein surfaces → recognized as “misfolded proteins” by chaperones (e.g., Hsp70) → recruits PQC proteins → POI degradation via proteasome/lysosomeHyt-9 (binds ALK inhibitor, degrades ALK)(1) Lower molecular weight than PROTACs; (2) No compensatory upregulation of POI; (3) Significant in vivo tumor suppressionDual-PROTAC (Dual-Target PROTAC)(1) Two POI-binding ligands; (2) Linker; (3) Single E3 ubiquitin ligase ligandSimultaneously binds two POIs (different pathways) and E3 → induces ubiquitination of both → degradation by proteasomeEGFR-PARP Dual-PROTAC(1) Synchronous degradation of dual targets, synergistic inhibition of disease pathways; (2) Suitable for complex diseases (multi-target-driven)SARD/SERD (Receptor Degraders)- SARD: AR-binding ligand;- SERD: ER-binding ligandBinds to AR/ER → induces conformational changes → promotes ubiquitination and degradation → inhibits hormone signaling pathways (androgen/estrogen)SARD:ARV-110ARV-766CC-94,676(1) Precisely targets hormone receptor-related diseases (prostate cancer, breast cancer); (2) Direct receptor degradation, more thorough signal inhibitionLysosomal-based TPDLYTACs (Lysosome-Targeting Chimeras)(1) POI-binding receptor; (2) Lysosomal targeting signal (e.g., ASGPR ligand)Guides “POI-LYTAC” complex into lysosome via endocytosis → degraded by lysosomal hydrolasesJW-9(1) Degrades extracellular/membrane proteins; (2) Regulates tumor immune microenvironment (e.g., enhances NK cell anti-liver cancer effect)ABTACs (Antibody-Based PROTACs)Antibody with dual antigen-binding arms (binds cell surface target membrane protein and E3)Forms “target membrane protein-ABTAC-E3” ternary complex → endocytosed into cells → enters lysosome → target protein degraded by hydrolasesPD-L1-targeted ABTACs(1) High specificity and affinity, low off-target effects; (2) Targets membrane proteins inaccessible to traditional small molecules; (3) Expands druggable targetsAUTACs (Autophagy-Targeting Chimeras)(1) POI-specific binding agent; (2) Degradation tag (guanine derivative, mimicking S-guanosylation)Degradation tag induces K63 ubiquitination of POI → recognized by selective autophagy pathway → transported to autophagy-lysosome for degradationAUTACs targeting HTT65Q aggregates and mitochondria(1) Degrades protein aggregates and damaged organelles; (2) Dependent on autophagy pathway, suitable for autophagy-related diseasesATTECs (Autophagy-Tethering Compounds)(1) LC3-binding molecule (e.g., GW5074); (2) Lipid droplet (LD)-specific binding molecule (e.g., Sudan IV/III); (3) LinkerOne end binds to LDs/neutral lipids, the other binds to autophagosome protein LC3 → forms “LD-ATTEC-LC3” complex → engulfed by autophagosomes → degraded in lysosomesNo specific representative molecules(1) Precisely degrades LD-related substances; (2) Degradation products recyclable for energy, reducing cellular metabolic burdenCMA-based TPDCMA-Dependent DegradersDependent on HSP70 and LAMP2A, specific structure not explicitly mentionedHSP70 recognizes POI to form a complex → binds to lysosomal membrane LAMP2A → LAMP2A oligomerization forms a transmembrane channel → POI unfolds and enters lysosome for degradationNo specific representative molecules(1) High specificity (dependent on HSP70-LAMP2A recognition); (2) Controllable degradation process, reducing off-target impact Table 1The current mainstream TDP types and representative moleculesMajor TPD categorySpecific molecular classMolecular structure compositionMechanism of actionRepresentative molecules/examplesKey advantagesUPS-based TPDPROTACs (Proteolysis-Targeting Chimeras)(1) Protein of Interest (POI)-binding ligand; (2) Linker (connects ligands); (3) E3 Ubiquitin Ligase ligand (e.g., CRBN, VHL)Forms a “POI-PROTAC-E3” ternary complex → ubiquitination of POI → degradation of POI into short peptides by proteasome;ARV-471ERD-12,310 AARV-471ACBI3ARV825(1) Non-occupancy-driven, recyclable; (2) Low dosage, low resistance risk, long-lasting efficacy; (3) Expands druggable targets (e.g., KRAS)Molecular GluesSmall molecules, no Linker componentBinds to E3 ubiquitin ligase (e.g., CRBN, VHL) → alters conformation/exposes new binding interfaces → induces POI-E3 interaction → ubiquitination and degradation of POIThalidomide and derivatives(1) Small molecular weight; (2) Excellent oral absorption and cellular penetration; (3) No need to bind both POI and E3HyT (Hydrophobic Tagging Degraders)(1) POI-binding ligand; (2) Linker; (3) Hydrophobic tag (e.g., icariene, D-cycloconjugated artemisinin)Mimics hydrophobic amino acids on protein surfaces → recognized as “misfolded proteins” by chaperones (e.g., Hsp70) → recruits PQC proteins → POI degradation via proteasome/lysosomeHyt-9 (binds ALK inhibitor, degrades ALK)(1) Lower molecular weight than PROTACs; (2) No compensatory upregulation of POI; (3) Significant in vivo tumor suppressionDual-PROTAC (Dual-Target PROTAC)(1) Two POI-binding ligands; (2) Linker; (3) Single E3 ubiquitin ligase ligandSimultaneously binds two POIs (different pathways) and E3 → induces ubiquitination of both → degradation by proteasomeEGFR-PARP Dual-PROTAC(1) Synchronous degradation of dual targets, synergistic inhibition of disease pathways; (2) Suitable for complex diseases (multi-target-driven)SARD/SERD (Receptor Degraders)- SARD: AR-binding ligand;- SERD: ER-binding ligandBinds to AR/ER → induces conformational changes → promotes ubiquitination and degradation → inhibits hormone signaling pathways (androgen/estrogen)SARD:ARV-110ARV-766CC-94,676(1) Precisely targets hormone receptor-related diseases (prostate cancer, breast cancer); (2) Direct receptor degradation, more thorough signal inhibitionLysosomal-based TPDLYTACs (Lysosome-Targeting Chimeras)(1) POI-binding receptor; (2) Lysosomal targeting signal (e.g., ASGPR ligand)Guides “POI-LYTAC” complex into lysosome via endocytosis → degraded by lysosomal hydrolasesJW-9(1) Degrades extracellular/membrane proteins; (2) Regulates tumor immune microenvironment (e.g., enhances NK cell anti-liver cancer effect)ABTACs (Antibody-Based PROTACs)Antibody with dual antigen-binding arms (binds cell surface target membrane protein and E3)Forms “target membrane protein-ABTAC-E3” ternary complex → endocytosed into cells → enters lysosome → target protein degraded by hydrolasesPD-L1-targeted ABTACs(1) High specificity and affinity, low off-target effects; (2) Targets membrane proteins inaccessible to traditional small molecules; (3) Expands druggable targetsAUTACs (Autophagy-Targeting Chimeras)(1) POI-specific binding agent; (2) Degradation tag (guanine derivative, mimicking S-guanosylation)Degradation tag induces K63 ubiquitination of POI → recognized by selective autophagy pathway → transported to autophagy-lysosome for degradationAUTACs targeting HTT65Q aggregates and mitochondria(1) Degrades protein aggregates and damaged organelles; (2) Dependent on autophagy pathway, suitable for autophagy-related diseasesATTECs (Autophagy-Tethering Compounds)(1) LC3-binding molecule (e.g., GW5074); (2) Lipid droplet (LD)-specific binding molecule (e.g., Sudan IV/III); (3) LinkerOne end binds to LDs/neutral lipids, the other binds to autophagosome protein LC3 → forms “LD-ATTEC-LC3” complex → engulfed by autophagosomes → degraded in lysosomesNo specific representative molecules(1) Precisely degrades LD-related substances; (2) Degradation products recyclable for energy, reducing cellular metabolic burdenCMA-based TPDCMA-Dependent DegradersDependent on HSP70 and LAMP2A, specific structure not explicitly mentionedHSP70 recognizes POI to form a complex → binds to lysosomal membrane LAMP2A → LAMP2A oligomerization forms a transmembrane channel → POI unfolds and enters lysosome for degradationNo specific representative molecules(1) High specificity (dependent on HSP70-LAMP2A recognition); (2) Controllable degradation process, reducing off-target impact The current mainstream TDP types and representative molecules ARV-471 ERD-12,310 A ARV-471 ACBI3 ARV825 SARD: ARV-110 ARV-766 CC-94,676 Studies of TPD in diseases TPD in cancer TPD have shown great potential in preclinical studies of many diseases due to their unique ability to efficiently remove proteins. Especially in tumors, protein level changes play a key role in tumorigenesis, development and treatment (Fig. 3A) [101]. Fig. 3Schematic illustration of the mechanisms and applications of TPD in multiple disease areas. (A) In oncology and hormone related regulation: TPD targets BRD4 to modulate c-Myc and proto-oncogene expression and regulates the balance between ER and AR. (B) In neurodegenerative processes: TPD acts on GSK3β and tau proteins to mediate their inhibition. (C) In inflammation and immunity: TPD enables degradation of inflammatory factors, inhibition of inflammatory macrophage phenotypes, and exerts immune regulation effects Schematic illustration of the mechanisms and applications of TPD in multiple disease areas. (A) In oncology and hormone related regulation: TPD targets BRD4 to modulate c-Myc and proto-oncogene expression and regulates the balance between ER and AR. (B) In neurodegenerative processes: TPD acts on GSK3β and tau proteins to mediate their inhibition. (C) In inflammation and immunity: TPD enables degradation of inflammatory factors, inhibition of inflammatory macrophage phenotypes, and exerts immune regulation effects BRD4 plays a complex and important role in the development of tumors. BRD4 recognizes and binds to acetylated histones through its bromodomain, thereby localizing to specific regions of chromatin and activating critical gene expression in tumors [102, 103]. Simon T Jakobsen et al. showed that BRD4 directly binds to the MYC promoter or enhancer, promoting its high expression and resulting in tumorigenesis [104]. In addition, some anti-apoptotic genes, such as B-cell lymphoma 2 (BCL-2) and Cyclin D1 (CCND1), were also suppressed with the high expression of BRD4, which led to the suppression of normal apoptotic processes [105]. In recent years, some BRD4-PROTACs have been gradually developed. ARV-825 is a typical BRD4-degrading PROTACs. Recent studies have shown that ARV-825 exhibits excellent BRD4 degradation and inhibits MYC action in many tumors, including T-cell acute lymphoblastic leukemia [106], melanoma [107], thyroid carcinoma [108], gastric cancer [109], etc., thus exhibiting significant antitumor activity. and inhibited the action of MYC, thus showing remarkable antitumor activity. In addition, ARV-763 showed similar effects as ARV-825. In a study of myeloma cell lines, ARV-825 exhibited similar BRD4 degradation as ARV763 [110]. AR plays an important role in many hormone-dependent tumors, such as prostate cancer and breast cancer. Unlike other factors, AR plays a dual role in tumors, either promoting tumor growth or inhibiting the growth of certain tumor cells [111]. For example, the AR gene is abnormally enhanced in prostate cancer [112], whereas in breast cancer [113], AR may antagonize estrogen receptor activity and act as a tumor suppressor. AR antagonists such as bicalutamide, enzalutamide, and apalutamide have been widely used and have achieved some efficacy. However, long-term drug resistance has limited the use of these drugs [114]. ARV-110 is a PROTACs that targets AR and exhibits sustained AR degradation and AR signaling inhibition [74]. ARV-110, an oral PROTAC AR degrader, remains under clinical investigation for metastatic castration-resistant prostate cancer (mCRPC) and has not yet obtained regulatory approval [115]. It is currently evaluated in Phase 1/2 open-label trials focusing on safety, tolerability, and anti-tumor activity in heavily pretreated patients who progressed on prior therapies like abiraterone or enzalutamide [116]. Similar to AR, GDC-0810, a PROTAC molecule targeting ER, induces ER degradation in estrogen receptor-positive breast cancer cells, thereby inhibiting tumor cell growth and proliferation [117]. ARV-471, an oral PROTAC ER degrader co-developed by Arvinas and Pfizer, is a key candidate for ESR1-mutated ER+/HER2- advanced breast cancer [19]. Its clinical status is anchored by Phase 3 VERITAC-2 trial data, which showed in the ESR1-mutant subgroup a statistically significant progression-free survival benefit: 5.0 months vs. 2.1 months with fulvestrant, reducing disease progression/death risk by 43% (HR = 0.58, P < 0.001), alongside a 18.6% objective response rate vs. 4.0% with fulvestrant. Notably, it demonstrated a manageable safety profile, with most treatment-related adverse events (TRAEs) being Grade 1/2, Grade ≥ 3 TRAEs occurred in 23.4%, and discontinuation due to TRAEs was only 2.9% [118]. BTK is a core driver of B-cell tumors such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) [119, 120]. Recently, PROTACs targeting BTK have also entered the clinical trial phase. NX-2127 is a bifunctional degrader that acts on both BTK and transcription factors IKZF1/3, exerting a more potent antitumor efficacy [121]. NX-5948 specifically focuses on BTK degradation, lacks IKZF degradation activity, thereby reducing potential immunological side effects [122]. Abnormal and sustained activation of STAT3 permeates the entire process of tumorigenesis, progression, metastasis, and drug resistance [123]. SD-36 is the first STAT3-targeting PROTAC molecule to enter clinical trials. Relevant studies have shown that SD-36 exhibits significant tumor-suppressive efficacy in multiple tumor models and remains effective against advanced tumors [124]. G1 to S phase transition 1 (GSPT1), also known as eRF3a, is mainly involved in protein translation termination. GSPT1 is highly expressed in a variety of tumors and has pro-tumorigenic effects. Yongbo Liu et al. recently developed a molecular glue named YB-3-17, which can potently inhibit mTOR and selectively degrade GSPT1. RNA sequencing analysis highlighted that YB-3-17 is superior to mTOR inhibitors and can safely and effectively inhibit the growth of mouse tumors [125]. CDK4/6 is closely related to the cell cycle, and in many types of cancer, the CDK4/6 pathway is frequently aberrantly activated, leading to uncontrolled cell cycle control and unlimited proliferation. For example, mutant activation of CDK4 is seen in melanoma [126]. Abnormal activation of CDK4/6 keeps cells in S-phase and promotes tumor growth, and also affects pathways such as glucose metabolism, apoptosis, and DNA repair, which further enhances tumor adaptive capacity [127]. Pal-pom is a PROTAC molecule designed to specifically degrade CDK4/6. Pal-pom is designed to specifically degrade CDK4/6. It can effectively inhibit the proliferation of cancer cells and overcome the drug resistance problem commonly associated with traditional CDK4/6 inhibitors and has demonstrated good anti-tumor activity in both cellular experiments and animal models [128]. DT2216 [57] targeting B-cell lymphoma-extra-large (BCL-XL is an important anti-apoptotic member of the BCL-2 family, which promotes tumor cell survival and drug resistance), 4 H-5P-M targeting Hexokinase 2 (HK2, one of the key enzymes of glycolysis, located in the outer membrane of the mitochondrion and highly expressed in tumor cells), etc., have all demonstrated their value of research in the treatment of tumors. The research value of 4 H-5P-M has been demonstrated in tumor therapy [129]. Neurodegenerative diseases Neurodegenerative diseases, including AD [130], Parkinson’s Disease (PD) [131] and Huntington’s Disease (HD) [132], are centered on the inability to remove disease-causing proteins such as β-amyloid [133] and α-synuclein [134] from the brain and their abnormal deposition in the brain (Fig. 3B). The need for such diseases is very much in line with the original design of TPD, and many scholars are currently working on the development of relevant TPD drugs. Numerous studies have shown that the typical pathology of AD is characterized by the accumulation of large amounts of β-albumin (Aβ) [135] and the hyperphosphorylation of tau proteins in the brain [136]. Glycogen Synthase Kinase 3β (GSK3β) is hyperactivated in the brains of AD patients and is associated with tau- and Aβ-mediated) toxicity. The PROTAC named PT-65 developed by Lailiang Qu et al. this year has shown promising results in the treatment of AD. PT-65 was able to effectively inhibit GSK3β and Aβ-mediated tau protein hyperphosphorylation in a dose-dependent manner and protect SH-SY5Y cells from Aβ-induced cellular damage [137]. On the other hand, PROTAC can act directly with tau proteins. In a 2021 study, Weijin Wang et al. developed a small-molecule PROTAC named C004019, which was able to recruit both tau and E3 ligase, VHL, to achieve selective ubiquitination and hydrolysis of tau proteins. Subcutaneous administration of C004019 significantly reduced tau levels and improved synaptic and cognitive functions in the brains of wild-type, hTau transgenic and 3xTg-AD mice (a transgenic mouse of AD) [138]. The primary etiology of PD has not been fully explored but is associated with abnormal aggregation of α-synuclein. Neuronal loss in certain regions of the substantia nigra and intracellular assembly of α-synuclein are pathologic hallmarks of PD [139]. In a recent study by Jack Wuyang Jin, a protac named Tat-βsyn-degron effectively reduced the level of α-synuclein in cell cultures and animals through proteasomal degradation [140]. Some other related proteins, such as Leucine-rich repeat kinase 2 (LRRK2) is one of the signature proteins of PD, XL01126 is a multiple isoforms LRRK2 protein PROTAC developed in 2022, which achieved good therapeutic effects in ex vivo PD modeling experiments [141]. PROTACs can also be used to modulate the cellular state of PD. For example, a recent study by Ligang Mei showed that PROTAC named HTT65Q ameliorates mitochondrial dysfunction and protects against apoptosis induced by FCCP, a mitochondrial stressor, by targeting dysfunctional mitochondria and promoting the degradation of mitochondrial autophagy in a cellular model of Parkinson’s disease. This provides a new way of thinking about the treatment of PD, i.e., shifting from proteins to metabolically abnormal organelles [98]. Unfortunately, the blood-brain barrier (BBB) serves as a key barrier limiting the translational application of TPDs in neurodegenerative diseases [142]. By optimizing the molecular structure, the molecular weight of TPDs is reduced to the range of 400–600 Da, the LogP value is adjusted to 2–4, and the number of hydrogen bond donors/acceptors is decreased to enhance passive diffusion capacity. ARV-102, by optimizing the linker length and E3 ligand structure, achieves effective enrichment in the brains of mice after oral administration, and its degradation potency against the target protein is 100 times higher than that of traditional kinase inhibitors [143]. In addition, leveraging the receptor-mediated transcytosis (RMT) mechanism is also an effective strategy: TPDs are conjugated with ligands of receptors highly expressed at the blood-brain barrier (BBB), enabling targeted delivery via endocytosis [141, 144]. The use of PROTACs in the treatment of neurodegenerative diseases is one of the ideal and promising therapeutic strategies. However, the current use of PROTACs in the treatment of neurodegenerative diseases still faces many problems. One of the ultimate and limiting factors in the treatment of neurodegenerative diseases is the blood-brain barrier. Breaking the blood-brain barrier and delivering drugs to the brain is just as important as removing denatured proteins, and this is the challenge that PROTACs should overcome in these diseases. Inflammation and immunity The process of inflammation and immunity involves numerous proteins, including cytokines, inflammatory factors, and related signaling pathway proteins, among others (Fig. 3C) [145]. Prolonged activation of inflammation and immunity is accompanied by the upregulation of some proteins. TPD regimen facilitates the complete amelioration of protein expression abnormality during inflammation and immune abnormalities and is one of the ideal and promising therapeutic options [146]. Two studies by Junli Huang have shown that PROTACs can be used to efficiently degrade BTK and reduce the activation of nuclear factor-κB (NF-κB), which plays an important role in inflammation onset and sustained inflammatory activation. In this study, the team developed compound 15 (PROTACs) to inhibit interleukin 1β (IL-1β), interleukin 6 (IL-6), and interleukin 4 (IL-1β) by scavenging BTK [147, 148]. TPD has been shown to be effective in a number of diseases caused by abnormal inflammation, such as enteritis (including Crohn’s disease and ulcerative colitis) PROTACs for prolyl hydroxylase (PHD) have been shown to exhibit protein inhibitory activity that exceeds that of the small molecule inhibitors of PHD by two to three orders of magnitude.The reduction in the activity of PHD facilitates the restoration of the normal level of the hypoxia inducible factor, Hif-1/2α, and the alleviation of inflammation of the intestine [149]. In response to acute inflammation caused by infection, Rentang Huang et al. developed C-PROTAC, which acts on Z-DNA binding protein 1 (ZBP1) and effectively reduces ZBP1 protein levels, with a 3-fold higher degradation rate than conventional PROTAC. It significantly reduced the intense inflammatory response due to viral infection, and thus reduced the incidence of pulmonary edema during the acute inflammatory phase of viral infection [150]. The effects of PROTACs on inflammation are also manifested in phenotypic changes on macrophages, one of the important immune cells for the initiation and persistence of inflammation [151]. Histone deacetylase 3 (HDAC3), has a multidimensional impact on macrophage function by regulating their transcriptional programs, signaling pathways, and metabolic status. Primarily, HDAC3 enhances the activation of pro-inflammatory genes and promotes macrophage polarization toward the M1 phenotype via NF-κB or histones, such as H3K9 and H3K27. At the same time, HDAC3 inhibits the acetylation of transcription factors such as PPARγ and CREB, and consequently inhibits macrophage polarization to the M2 phenotype [152]. The role of PROTACs in immunity is mainly reflected in the development of therapeutic regimens for autoimmune diseases. BTK regulation of B cells is a central aspect of systemic lupus erythematosus (SLE), and elevated BTK activates monocyte and macrophage activity and amplifies inflammatory responses, further accelerating the course of SLE. In a study by Can Zhu et al. a few years ago, a BTK-PROTAC called L18I effectively reduced serum Immunoglobulin M (IgM) and Immunoglobulin M (IgG) in mice, which led to a reduction in mortality in SLE mice [153]. Autoimmune diseases are also regulated by certain proteins, such as Interleukin-1 receptor associated kinase 4 (IRAK4). IRAK4 initiates downstream signaling cascades via phosphorylation, activates the NF-κB and MAPK pathways, amplifies aberrant inflammatory responses, and exerts a certain role in tumor metastasis and tolerance [154, 155]. KT-474 is the first identified PROTAC for the treatment of autoimmune diseases, exhibiting superior efficacy compared to traditional therapeutic approaches in atopic dermatitis, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Additionally, for certain tumors, KT-474 (note: corrected from the possible typo “KT-747” for consistency) selectively inhibits the NF-κB pathway, inducing cell cycle arrest and apoptosis [156, 157]. Overall, TPD for the treatment of both inflammatory and immune disorders has demonstrated several or tens of times higher therapeutic efficacy than conventional inhibitors and has shown favorable long-term therapeutic outcomes. It is promising to be developed as a new class of validated inhibitors as drugs, which is a transgressive step forward for inflammatory and immune-related diseases. TPD and biomaterials: improvement of targeting and treatment efficiency Although TPD have been extensively studied in many disease areas, including tumors, Neurodegenerative Diseases as well as inflammation and immunity diseases, and have provided new therapeutic options for the above mentioned diseases, TPD still have some limitations [158]. Limited by their long-chain or large-molecule structures, TPD have extremely poor water solubility and in vivo penetration, while the undifferentiated cellular effects of established TPD also lead to a significant risk of systemic toxicity [159]. In recent years, with the continuous development of nanodrug delivery systems, researchers have developed a series of nanodrug delivery systems for different diseases and tissues (Fig. 4 Table 2) [160, 161]. Due to the advantages of nano-drug delivery systems, which can improve the solubilization and utilization of drugs, can deliver drugs in a targeted manner, can confer drug-responsive release ability and can reduce off-target toxicity of drugs, nano-drug delivery systems are a perfect fit with the limitations of TPD and are expected to expand the value of the application of TPD [162, 163]. Fig. 4Schematic illustration of PROTAC loaded nanoparticles for targeted delivery and stimulus responsive release. PROTACs are encapsulated into nanoparticles, which can target multiple tissues including Lung, Intestinal, Kidney, Ovarian, and Prostate. Upon exposure to stimuli such as ROS, pH changes, Light, Sound, or Protease in the target microenvironment, PROTACs are released from the nanoparticles Schematic illustration of PROTAC loaded nanoparticles for targeted delivery and stimulus responsive release. PROTACs are encapsulated into nanoparticles, which can target multiple tissues including Lung, Intestinal, Kidney, Ovarian, and Prostate. Upon exposure to stimuli such as ROS, pH changes, Light, Sound, or Protease in the target microenvironment, PROTACs are released from the nanoparticles Table 2Targeted delivery strategy and main effects of PROTACType of vectorDiseasesReleaseEffect of treatmentPassive targeting nanocarriers (GM NPs, selenium nanosystems, gold nanoparticles)Tumor (IDO, P300, ALK fusion protein)EPR effect in tumorsIt is enriched in tumor sites, degrades target proteins, and inhibits tumor growth/metastasisActive-targeting peptide-modified lipid nanoparticlesTumor, STAT3Tumor IGF2R receptor bindingEnhanced PROTAC uptake and accumulation by tumor cellsBiomimetic nanocarriers (M2 macrophage membrane based)Atherosclerosis (TRIM24)Inflammatory chemotactic aggregation of macrophagesChanges in macrophage phenotype and alleviates atherosclerosisBiomimetic nanocarriers (tumor cell membrane camouflage)Homologous pancreatic cancerIdentification of tumor cell characteristicsImprove serum stability and biocompatibility, and accurately target tumorsBiomimetic nanocarriers (albumin bound nanoparticles)4T1 tumor BRD4Albumin spontaneous binding and tumor enrichmentThe highest intracellular concentration was reached within 12 h, and PROTAC was efficiently deliveredRedox responsive nanocarriers (cationic liposomes, PDSA, self-polymerized nanoparticles)HCC STAT3, tumor BRD4/c-MycROS, glutathioneActivate prodrugs/break chemical bonds, degrade target proteins, and inhibit tumorsPh-responsive nanocarrier (disulfide-bonded PLGA)Lung cancer, BRD4Tumor acidic microenvironment (pH 6.0-6.5)PROTAC is released to induce apoptosis of cancer cells and promote tumor regressionUltrasound-activated PROTAC prodrug carrier (NPCe6 + PRO)Pancreatic cancer, BRD4Ultrasound irradiation + ROSSDT and ICD were achieved, BRD4 was degraded, and PD-L1 up-regulation was reversedNIR light-activated nanocages (UMSNs@phoBET1)Liver cancer, BRD4980 nm near infrared lightControlled release of PROTAC degraded target proteins and induced apoptosis of cancer cellspH/histone B dual-responsive nanocarriersCDK4/6 in rectal cancerAcidic microenvironment + histone BIt promotes tumor invasion and internalization and releases PROTAC to degrade target proteins Table 2Targeted delivery strategy and main effects of PROTACType of vectorDiseasesReleaseEffect of treatmentPassive targeting nanocarriers (GM NPs, selenium nanosystems, gold nanoparticles)Tumor (IDO, P300, ALK fusion protein)EPR effect in tumorsIt is enriched in tumor sites, degrades target proteins, and inhibits tumor growth/metastasisActive-targeting peptide-modified lipid nanoparticlesTumor, STAT3Tumor IGF2R receptor bindingEnhanced PROTAC uptake and accumulation by tumor cellsBiomimetic nanocarriers (M2 macrophage membrane based)Atherosclerosis (TRIM24)Inflammatory chemotactic aggregation of macrophagesChanges in macrophage phenotype and alleviates atherosclerosisBiomimetic nanocarriers (tumor cell membrane camouflage)Homologous pancreatic cancerIdentification of tumor cell characteristicsImprove serum stability and biocompatibility, and accurately target tumorsBiomimetic nanocarriers (albumin bound nanoparticles)4T1 tumor BRD4Albumin spontaneous binding and tumor enrichmentThe highest intracellular concentration was reached within 12 h, and PROTAC was efficiently deliveredRedox responsive nanocarriers (cationic liposomes, PDSA, self-polymerized nanoparticles)HCC STAT3, tumor BRD4/c-MycROS, glutathioneActivate prodrugs/break chemical bonds, degrade target proteins, and inhibit tumorsPh-responsive nanocarrier (disulfide-bonded PLGA)Lung cancer, BRD4Tumor acidic microenvironment (pH 6.0-6.5)PROTAC is released to induce apoptosis of cancer cells and promote tumor regressionUltrasound-activated PROTAC prodrug carrier (NPCe6 + PRO)Pancreatic cancer, BRD4Ultrasound irradiation + ROSSDT and ICD were achieved, BRD4 was degraded, and PD-L1 up-regulation was reversedNIR light-activated nanocages (UMSNs@phoBET1)Liver cancer, BRD4980 nm near infrared lightControlled release of PROTAC degraded target proteins and induced apoptosis of cancer cellspH/histone B dual-responsive nanocarriersCDK4/6 in rectal cancerAcidic microenvironment + histone BIt promotes tumor invasion and internalization and releases PROTAC to degrade target proteins Targeted delivery strategy and main effects of PROTAC Tissue targeting nanodelivery systems carrying TPD Nanoparticles are able to deliver TPD precisely to the lesion site through multiple mechanisms to achieve efficient treatment and reduce damage to normal tissues [164]. Tissue targeting is achieved through passive targeting [165], active targeting [29] and physical targeting [166]. Passive targeting is mainly designed for drug delivery to tumors as well as inflammation. Due to the Enhanced Permeability and Retention Effect (EPR) effect in tumor tissues [167], nanoparticles carrying TPD are enriched at the tumor site, and the size and shape of the nanoparticles have a large impact on the EPR effect, and nanometers in the range of 10–200 nm are usually designed for ERP-based PROTAC delivery [168]. Inspired by the guanine structure of the AUTAC molecule, Yazhen Wang et al. developed supramolecular artificial nano-AUTACs (GM NPs) designed from the AUTAC molecule GN [indoleamine 2,3-dioxygenase (IDO) degrader] and the nucleoside analog methotrexate (MTX) via supramolecular interactions for tumor-specific protein degradation. Through EPR effects their nanostructures allow precise localization and delivery into cancer cells for modulation of tumor-associated macrophages, activation of dendritic cells, and induction of autophagy. Autophagy promotes the release of GN-degraded immunosuppressive IDOs, which further enhance effector T cell activity and inhibit tumor growth and metastasis [169]. The P300 peptide-targeted degradation of RPOTAC drug developed by Dize Zhang et al. loaded with a selenium nanodelivery system enhanced the enrichment of PROTAC at the tumor site and showed effective P300 clearance and tumor inhibition in both AR-negative/positive mouse prostate cancer models [170]. Gold nanoparticles developed by Yingming Wang efficiently enriched PROTAC at the site of anaplastic lymphoma kinase (ALK) and significantly reduced the level of ALK fusion proteins through the EPR effect and specifically inhibited the proliferation of NCI-H2228 cells in a dose- and time-dependent manner [171]. Active targeting is the precise delivery of PROTACs to the target location by modifying the surface of the nanoparticles with a characteristic targeting antibody that is able to bind to a specific receptor on the diseased cell or tissue [29]. Haohao Song et al. developed a paper-based nanoparticle delivery system for PROTACs by modifying insulin-like growth factor 2 receptor (IGF2R)-targeting peptide on the surface of lipid nanoparticles and loading targeted degradation of activator of STAT3, which utilized up-regulated IGF2R in tumor tissues to strongly increase the accumulation and increased PROTACs uptake in tumor cells [172]. In addition, biomimetic nanoparticles play an important role in the active targeted delivery of RPOTAC. By utilizing the structural and functional characteristics of natural biological systems, the structural core of which mimics the targeting mechanisms in natural organisms, biomimetic nanoparticles coated with cell membranes are the most common [173, 174]. In a study by Jiong-hua Huang, researchers designed macrophage (M2)-membrane-based PROTAC mimetic nanocarriers that utilize inflammatory chemotactic aggregation of macrophages to achieve inflammatory targeting and were used to abrogate the effect of the Tripartite Motif-Containing 24 (TRIM24) protein on macrophage phenotypes in atherosclerosis, which greatly mitigated atherosclerosis in high-fat, high-cholesterol-dieted (ApoE−/−) mice with atherosclerotic plate progression [175]. Ruyu Fan et al. constructed tumor-targeted biomimetic nanoparticles using tumor cell membrane camouflage, and tumor cell membrane camouflage resulted in good in vivo serum stability, controlled drug release profile, good biocompatibility and immunocompatibility, as well as outstanding targeting ability against homologous pancreatic cancer cells of CM8988-PIPD [176]. The construction of biomimetic nanoparticles using part of the protein function also plays an important role in PROTAC delivery, compared to the construction of biomimetic nanoparticles using cell membranes, using plasma albumin as can be accumulated in targeted tumor tissues, Hanhee Cho et al. constructed nanoparticles loaded with targeted BRD4 proteins by sulfhydryl-maleimide bonding chemistry with spontaneous binding to albumin, which in circulating similar to normal albumin, while at 4T1 tumor cells they were actively endocytosed and reached the highest intracellular level within 12 h [177]. TPD loading and releasing Redox-responsive release TPD is a commonly used tool in nanocarrier design, in which nanocarriers are endowed with oxidizing/reducing chemical bonds during the nanocarrier design phase, so that chemical bond breakage occurs in either a high free radical (ROS) environment or a high glutathione environment, resulting in the release of the drug [28, 178]. The redox response loads and releases drugs well in a variety of disease models. For example, in the tumor environment, due to highly active cells, cellular energy metabolism is much higher than in normal tissues, which results in the presence of large amounts of ROS aggregation in tumor tissues and causes the body to compensatingly elevate the expression of reduced glutathione used to resist high ROS [179]. Xuan Wang et al. promoted the lysosomal escape of the prodrug PROTAC by constructing nanoliposome-loaded prodrugs in cationic liposomes.PROTAC prodrugs were activated by up-regulated ROS levels in hepatocellular carcinoma and effectively degraded STAT3 for chemical reprogramming [180]. Similarly, apoptosis due to inflammation leads to abnormal mitochondrial function causing ROS leakage and accumulation in inflamed tissues. Therefore, redox-responsive PROTAC release can be used in the development of therapeutic drugs for a variety of diseases.The polydisulfide amide (PDSA) nanocarrier developed by Hai-jun Liu et al. released ARV-771 for on-demand degradation in the tumor environment by responding to glutathione in tumors (Bromodomain-containing protein, BRD4) and successfully reduced the expression of the oncogene c-Myc [162]. Designing PROTACs as self-polymerizing nanoparticles and responsive to glutathione similarly enhances the tumor-targeting effect of PROTACs and increases the bioavailability of PROTACs. In a study by Ni-Yuan Zhang et al., PROTACs were designed as in situ self-assembled PROTAC nanoparticles using intermolecular hydrogen bonding interactions and constructed for GSH-responsive degradation, and achieved up to 79% dose-dependent protein degradation and tumor growth inhibition in vivo [25]. A variety of diseases produce local pH changes. In tumors, for example, long-term cellular energy metabolism causes lactic acid to accumulate in large quantities in the tumor microenvironment, which makes the tumor microenvironment slightly acidic (pH between 6.0 and 6.5), and this pH change that distinguishes it from that of normal tissues also provides an environmental condition for responsive release of nanomedicine carriers [181]. Based on this, Xiaoling Guan developed pH-responsive disulfide bond-linked polylactic acid-co-glycolic acid nanodrug carriers, which released PROTAC targeting BRD4 protein in the microacidic environment and induced apoptosis of lung cancer cells through the degradation of BRD4, thus contributing to the tumor regression [178]. An ultrasound-activated prodrug of PROTACs was developed and used for the treatment of pancreatic tumor-bearing mice in a study by Ye Liu et al. [182]. In this protocol, US irradiation of the PROTAC prodrug, termed NPCe6 + PRO with deep tissue penetration capability, led to ce6-mediated ROS generation, facilitated sonodynamic therapy (SDT) and induced immunogenic cell death (ICD). At the same time, the generated ROS cleave the thione (TK) linker through the ROS response mechanism to achieve on-demand activation of PROTAC precursors in deep tissues. This prodrug activation leads to the degradation of the target protein BRD4 while reversing the upregulation of PD-L1 expression associated with the SDT process. Near-infrared (NIR) light has been widely studied and used in the design and drug-responsive release of nanoparticles. qi He et al. designed a photocontained PROTAC (phoBET1) and constructed a NIR-light-activatable PROTAC nanocage (UMSNs@phoBET1) for controllable degradation of target proteins. Under near-infrared light (980 nm) irradiation, the UMSNs@phoBET1 nanocage could be activated to degrade bromodomain-containing protein 4 (BRD4) and induce apoptosis in hepatocellular carcinoma cells by releasing the active PROTAC in a controlled mode [183]. Protease-responsive release nanoparticles are a type of nano PROTACs carriers designed based on enzyme-sensitive chemical bonds in polymers, including peptide bonds, glycosidic bonds, and ester bonds [165]. Compared with other drug release strategies, protease-responsive release has higher precision and controlled release characteristics [184]. Taking rectal cancer as an example, histone B is highly expressed in rectal cancer, Liuqing Yang et al. developed a pH/histone B dual-responsive release nano PROTAC carrier, which were dissociated for the first time (< 10 nm) in an acidic tumor microenvironment to promote tumor infiltration and cellular internalization. Ultimately, PROTACs degrading CDK4/6 were released into the cell with histone b cleavage [165]. In summary, while TPD exhibit substantial therapeutic potential across a spectrum of diseases including tumors, neurodegenerative disorders, and inflammatory/immune conditions, their clinical translation remains constrained by inherent limitations, poor aqueous solubility, inadequate in vivo tissue penetration, and systemic toxicity. Notably, nanodrug delivery systems have emerged as a transformative solution to address these bottlenecks, with their utility anchored in two synergistic core strategies: precision tissue-targeted delivery and stimuli-responsive drug release, which collectively enhance TPD efficacy while minimizing off-target adverse effects. For tissue targeting, passive targeting leverages the EPR effect to drive the accumulation of TPD-loaded nanoparticles at tumor or inflammatory foci, where nanoparticle size optimization is critical for maximizing EPR-mediated enrichment. Active targeting further refines spatial precision via surface functionalization, such as conjugation of IGF2R-targeting peptides to lipid nanoparticles, while biomimetic carriers confer superior biocompatibility, serum stability, and homologous targeting capabilities. Complementing targeting strategies, stimuli-responsive release mechanisms ensure spatiotemporally controlled TPD delivery, redox-responsive systems operate effectively in tumor/inflammatory microenvironments. pH-responsive carriers exploit the acidic tumor microenvironment to release BRD4-targeting PROTACs and physical stimuli enable on-demand activation. Additionally, protease-responsive systems offer heightened precision via enzyme-specific cleavage of polymer linkages. Collectively, these nanodelivery platforms significantly improve TPD solubility, bioavailability, and tissue specificity, while reducing systemic toxicity thereby expanding the therapeutic applicability of TPD. By integrating precision targeting and stimuli-responsive release, they lay a robust foundation for the development of more effective, personalized TPD-based therapies, addressing unmet clinical needs across diverse disease contexts. Conclusion In conclusion, TPD is a transformative drug discovery paradigm that uses endogenous cellular degradation systems to eliminate disease-causing proteins, outperforming traditional inhibitors especially for “undruggable” targets such as KRAS G12C and mutant BTK. Approaches such as PROTACs and LYTACs degrade intracellular/extracellular proteins effectively, with strong preclinical efficacy in cancer, neurodegenerative, and inflammatory diseases. Pioneering drugs like ARV-110 (prostate cancer) and ARV-471 (breast cancer) have entered clinical trials, confirming TPD feasibility. However, TPDs face major translational hurdles that temper overoptimism. First, pharmacokinetic issues persist: PROTACs heterobifunctional structure causes high molecular weight, poor solubility, and < 20% oral bioavailability, often requiring injections. Second, off-target toxicity is critical. Ternary complex formation (target–E3 ligase–TPD) can degrade unintended proteins. CRBN-based PROTACs, for example, cause thrombocytopenia via Ikaros/Aiolos degradation. Third, delivery is challenging: the blood-brain barrier blocks TPDs in neurodegenerative diseases, while solid tumor microenvironments limit accumulation. Nanodelivery systems improve targeting but lack precise spatiotemporal control. Fourth, clinical development is complex: no reliable biomarkers exist for real-time degradation monitoring, and TPDs synthesis cost and potential immunogenicity (e.g., LYTACs) limit accessibility. Novel E3 ligands, structural optimization, and tailored nanocarriers offer solutions. Ultimately, TPD leads next-generation drug development, but its potential to redefine precision medicine depends on resolving these translational challenges. Only through advances in chemistry, delivery, and clinical methods can TPDs fulfill their promise as transformative therapies.